Additional coverage pathways Because UHC evaluates each medication under its own clinical policy bulletin, additional FDA-approved indications can open separate coverage pathways sometimes through medical benefit rather than pharmacy benefit
From 2009-2011, CDR Oguntimein served as the social scientist reviewing consumer studies (label comprehension, self-selection and actual-use) study protocols and results submitted for prescription-to-over-the counter applications in the Division of Nonprescription Clinical Evaluation (DNCE), Center for Drug Evaluation and Research (CDER)
1 The safety and efficacy of compounded, oral, and microdosed medications, including treatments that have not been inspected and approved by the FDA, cannot be guaranteed
The MotherToBaby position MotherToBaby, a service of the Organization of Teratology Information Specialists, notes that while studies are limited, the available data on injectable semaglutide and tirzepatide suggest low risk during breastfeeding